Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.
A Massachusetts-based police department has published contact and salary details of Big Pharma CEOs in an effort to force industry to help manage opiate addiction.
Opioid addiction drug Suboxone lost market share in 2014 according to newly independent Indivior, whose management says it is not intimidated by increased competition.
The implementation of track and trace will drive the outsourcing of drug packaging and UDG Healthcare is well-placed to benefit, according to a UK broking firm.
Almac’s subsidiary Galen has licensed UK sales and marketing rights to an emergency pain drug nicknamed the “green whistle” from Australian firm Medical Developments International (MVP).
The Center for Lawful Access and Abuse Deterrence (CLAAD) is working with the US Food and Drug Administration (FDA) on legislation for abuse-deterrent technology in opioids, its directors tell in-PharmaTechnologist.com.
Janssen Pharmaceuticals is prepared for Tramadol's reclassification by the US Drug Enforcement Administration (DEA) and says the supply of its versions of the opioid analgesic will not be interrupted.
Acura has reacquired the rights to its opioid abuse-deterrent technology from Pfizer and is looking for pharma partners to relaunch its oxycodone HCL drug Oxecta.
Anticipated demand for the drug Exparel has led to a contract win for Patheon, though NDA holder Pacira says it will maintain control of all aspects of the manufacturing process.
US-based BioDelivery Sciences International (BDSI) has selected Quintiles to provide a range of services to support the expected launch of Bunavail (buprenorphine and naloxone buccal film), a maintenance treatment for opioid dependence.
European regulators have been accused of making “no attempt” to counter misuse of prescription drugs in comparison with North American efforts to reformulate and restrict addictive drugs, according to a Canadian firm testing the abuse potential of medicines.
Production of BioDelivery Sciences International’s (BDSI) chronic pain treating drug, ONSOLIS, has resumed after a temporary voluntary shut down at contract manufacturers, Aveva Drug Delivery Systems.
Drug delivery company Monosol Rx and partner Reckitt Benckiser Pharmaceuticals have received US Food and Drug Administration (FDA) clearance to market a sublingual film formulation of the opioid dependence treatment Suboxone.
Penwest Pharmaceuticals raises guidance citing Opana ER royalties, deals and patent settlements as Q2 highlights; but warns that job cuts likely under cost cutting plan.
Chemicals firm Durect will supply drugmaker King Pharmaceuticals with two excipients used in the manufacture of the candidate anti-abuse painkiller Remoxy in an agreement signed last week.
China Aoxing Pharmaceutical, a specialist developer of pain management drugs, has received GMP accreditation for the new tablet production and packaging plant it has set up in Shijiazhuang.
Alpharma moved a step closer to bringing its morphine product Embeda to market after a US Food and Drug Administration advisory panel agreed that it is less susceptible to abuse than other opioid analgesic products.
API maker Cody Laboratories is targeting the lucrative analgesic and pain management markets with a new process that improves the efficiency of hydromorphone and hydrocodone manufacture.
in-PharmaTechnologist’s periodic round up of developments in the field of drug delivery includes BioDelivery initiating Phase I studies, success for Titan and a novel use for Viagra.
IntelliPharmaCeutics is ready to move into full-scale clinical
trials with a once-daily oral formulation of oxycodone based on the
company's ReXista abuse- and alcohol-resistant technology.
BioDelivery Sciences International (BDSI) has acquired the US
rights to the BEMA oral adhesive disc drug delivery technology for
$3m, with a further $4m to be paid at a later date.
The first ever non-steroidal anti-inflammatory drug (NSAID) to be
delivered via the nose has been developed, and its makers are
heralding it as "an important breakthrough in treating
pain".
GlaxoSmithKline (GSK) and Adolor have halted development of an
innovative drug designed to improve pain relief, amid concerns that
the drug could cause heart problems.
PainCeptor Pharma has announced it has been awarded a series of
patents for its drug development programs that focus on pain
management whilst avoiding the many detrimental side effects
associated with current pain drugs.
European Authorities recommended the first needle-free system for
acute postoperative pain for approval this week, which allows
patient-controlled delivery of fentanyl in post-operative pain
control.
Sugar is a useful excipient for use in medications because of its
ability to mask bitter tastes, but its use in drugs intended for
chronic use, or which reside in the mouth for an extended period,
raises the risk of dental caries.
A novel painkiller in development at Pain Therapeutics - based on a
technology that both improves dosing and prevents drug abuse - has
done well in a Phase III clinical trial.
UK biotechnology company Ionix Pharmaceuticals is gearing up for
acquisition by Vernalis in a share-based deal valuing Ionix at
around £12.5 million (€18.2m).
BioDelivery Sciences International has entered into a definitive
agreement to acquire all of the capital stock of fellow drug
delivery firm Arius Pharmaceuticals.
US biotechnology company Cephalon says that the US Federal Trade
Commission has approved its $385 million acquisition of CIMA Labs,
nearly a year after it outbid aaiPharma for the drug delivery
specialist.
UK drug delivery specialist SkyePharma received another welcome
boost yesterday with the news that its new formulation of morphine
had been approved in the US.
A new formulation technology developed by Rohm and Haas has the
potential to do away with the problem of prescription drug abuse
and make medicines safer in overdose. In-Pharmatechnologist.com
discussed this and other applications...